These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21849222)

  • 21. Distinct properties of prohormone thiol protease (PTP) compared to cathepsins B, L, and H: evidence for PTP as a novel cysteine protease.
    Azaryan AV; Hook VY
    Arch Biochem Biophys; 1994 Oct; 314(1):171-7. PubMed ID: 7944391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cu-mediated N-arylation of 1,2,3-triazin-4-ones: synthesis of fused triazinone derivatives as potential inhibitors of chorismate mutase.
    Shiva Kumar K; Adepu R; Sandra S; Rambabu D; Rama Krishna G; Malla Reddy C; Misra P; Pal M
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1146-50. PubMed ID: 22189133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of 3,6-diaryl-7H-thiazolo[3,2-b] [1,2,4]triazin-7-one derivatives as acetylcholinesterase inhibitors.
    Jin Z; Yang L; Liu SJ; Wang J; Li S; Lin HQ; Wan DC; Hu C
    Arch Pharm Res; 2010 Oct; 33(10):1641-9. PubMed ID: 21052939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rhenium inhibitors of cathepsin B (ReO(SYS)X (where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of inhibition.
    Mosi R; Baird IR; Cox J; Anastassov V; Cameron B; Skerlj RT; Fricker SP
    J Med Chem; 2006 Aug; 49(17):5262-72. PubMed ID: 16913715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new purification procedure of human kidney cathepsin H, its properties and kinetic data.
    Popović T; Brzin J; Kos J; Lenarcic B; Machleidt W; Ritonja A; Hanada K; Turk V
    Biol Chem Hoppe Seyler; 1988 May; 369 Suppl():175-83. PubMed ID: 3202963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tellurium-based cysteine protease inhibitors: evaluation of novel organotellurium(IV) compounds as inhibitors of human cathepsin B.
    Cunha RL; Urano ME; Chagas JR; Almeida PC; Bincoletto C; Tersariol IL; Comasseto JV
    Bioorg Med Chem Lett; 2005 Feb; 15(3):755-60. PubMed ID: 15664852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-formylpyrazolines and N-benzoylpyrazolines as novel inhibitors of mammalian cathepsin B and cathepsin H.
    Raghav N; Garg S
    Bioorg Chem; 2014 Dec; 57():43-50. PubMed ID: 25181676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.
    Raghav N; Singh M
    Eur J Med Chem; 2014 Apr; 77():231-42. PubMed ID: 24642566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
    Raghav N; Singh M
    Bioorg Med Chem; 2014 Aug; 22(15):4233-45. PubMed ID: 24913985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide ketobenzoxazole inhibitors bound to cathepsin K.
    McGrath ME; Sprengeler PA; Hill CM; Martichonok V; Cheung H; Somoza JR; Palmer JT; Janc JW
    Biochemistry; 2003 Dec; 42(51):15018-28. PubMed ID: 14690410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.
    Mura P; Camalli M; Casini A; Gabbiani C; Messori L
    J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amentoflavone and its derivatives as novel natural inhibitors of human Cathepsin B.
    Pan X; Tan N; Zeng G; Zhang Y; Jia R
    Bioorg Med Chem; 2005 Oct; 13(20):5819-25. PubMed ID: 16084098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclic guanidines: synthesis and antiplatelet activity of 4,6,7,8-tetrahydro-1H-imidazo[1,2-a]pyrazolo[3,4-d]pyrimidin-7-ones and 1,4,6,7,8,9-hexahydropyrazolo [3',4':4,5]pyrimido[2,1-c] [1,2,4]triazin-7-ones.
    Ferroni R; Simoni D; Orlandini P; Bardi A; Franze GP; Guarneri M
    Arzneimittelforschung; 1990 Dec; 40(12):1328-31. PubMed ID: 2095128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, crystal structure and anticancer activity of novel derivatives of ethyl 1-(4-oxo-8-aryl-4,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)formate.
    Sztanke K; Rzymowska J; Niemczyk M; Dybała I; Kozioł AE
    Eur J Med Chem; 2006 Apr; 41(4):539-47. PubMed ID: 16545495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a potent and selective noncovalent cathepsin S inhibitor.
    Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
    J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.
    Setti EL; Davis D; Janc JW; Jeffery DA; Cheung H; Yu W
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1529-34. PubMed ID: 15713422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity.
    Zhu Y; Cameron BR; Mosi R; Anastassov V; Cox J; Qin L; Santucci Z; Metz M; Skerlj RT; Fricker SP
    J Inorg Biochem; 2011 May; 105(5):754-62. PubMed ID: 21481817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, molecular docking, and biological activity of polyfluoroalkyl dihydroazolo[5,1-c][1,2,4]triazines as selective carboxylesterase inhibitors.
    Shchegol'kov EV; Makhaeva GF; Boltneva NP; Lushchekina SV; Serebryakova OG; Rudakova EV; Kovaleva NV; Burgart YV; Saloutin VI; Chupakhin ON; Bachurin SO; Richardson RJ
    Bioorg Med Chem; 2017 Aug; 25(15):3997-4007. PubMed ID: 28578994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arylamine based cathepsin K inhibitors: investigating P3 heterocyclic substituents.
    Shinozuka T; Shimada K; Matsui S; Yamane T; Ama M; Fukuda T; Taki M; Takeda Y; Otsuka E; Yamato M; Naito S
    Bioorg Med Chem; 2006 Oct; 14(20):6807-19. PubMed ID: 16829073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.